VKTX — Viking Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1607678 ·
Last close
$30.80
Market Cap
$3.58B
52W High
$37.50
52W Low
$28.16
ADV30
2,221,320
Next earnings
2026-07-29
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -164,125,000 | -158,325,000 | 608,242,000 | 118,116,000 | 106,325,000 |
| Dec 2025 | 0 | — | -164,738,000 | -157,662,000 | 715,729,000 | 165,810,000 | 76,667,000 |
| Sep 2025 | 0 | — | -98,561,000 | -90,787,000 | 739,415,000 | 100,376,000 | 26,385,000 |
| Jun 2025 | 0 | — | -74,574,000 | -65,561,000 | 827,851,000 | 33,880,000 | 32,390,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-340,330,000
Investing CF
$332,332,000
Financing CF
$88,167,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-4.14
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,005,871,000
Inventory
—
Receivables
—
ST Investments
$484,848,000
EBIT TTM
$-501,998,000
Pretax Income TTM
$-472,335,000
Interest Exp TTM
—
Analysts
18
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -393,342,000 | -359,639,000 | 715,729,000 | 76,667,000 | — | -278,685,000 |
| Dec 2024 | 0 | -150,921,000 | -109,963,000 | 908,321,000 | 28,043,000 | — | -87,790,000 |
| Dec 2023 | 0 | -100,827,000 | -85,895,000 | 368,490,000 | 20,071,000 | — | -73,376,000 |
| Dec 2022 | 0 | -70,355,000 | -68,867,000 | 168,529,000 | 23,207,000 | — | -48,397,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-4.54
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ERAS | Erasca, Inc. | $3.58B | $11.50 | — |
| ORKA | Oruka Therapeutics, Inc. | $3.56B | $59.06 | — |
| EWTX | Edgewise Therapeutics, Inc. | $3.61B | $33.56 | — |
| OGN | Organon & Co. | $3.52B | $13.41 | — |
| ACAD | ACADIA PHARMACEUTICALS INC | $3.64B | $21.26 | — |
News headlines (Yahoo Finance, 1h cache)
If Viking Therapeutics Is Acquired, Here’s Who Wins
2026-05-26 12:50 · Yahoo
Don't Buy Viking Therapeutics Stock Until You Read This
2026-05-26 00:20 · Yahoo
A Look At Viking Therapeutics (VKTX) Valuation As Shares Show Mixed Recent Returns
2026-05-25 13:15 · Yahoo
Eli Lilly Just Made a Game-Changing Move in the Billion-Dollar Weight Loss Drug Space. Here's What You Need to Know.
2026-05-25 09:25 · Yahoo
Is Viking Therapeutics a Top Takeover Target?
2026-05-23 20:51 · Yahoo
2 Stocks That Could Realistically Double by 2030
2026-05-22 07:35 · Yahoo
Could Viking Therapeutics Be the Next Eli Lilly?
2026-05-21 12:30 · Yahoo
Viking Therapeutics to Participate at Upcoming Investor Conferences
2026-05-21 11:05 · Yahoo
Watch Out, Eli Lilly and Novo Nordisk: Viking Therapeutics' Pill Could Crash the Weight-Loss Party
2026-05-19 01:05 · Yahoo
Three Biotechs That Are Top Takeover Targets
2026-05-18 17:55 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.